Metformin Versus Empagliflozin Monotherapy on Short-Term Glycemic Dairy: A true Experimental Study

Barakat Wathiq Alawdi; Jasem Hanoon Hashim  Al-Awadi; Abdulhamza Rajooj Hmood  Al-Ameri

doi:10.51699/cajmns.v7i2.3113

Authors

Barakat Wathiq Alawdi Biology Department, College of Science, University of Kerbala
Jasem Hanoon Hashim Al-Awadi Biology Department, College of Science, University of Kerbala
Abdulhamza Rajooj Hmood Al-Ameri Internal Medicine Department, College of Medicine, University of Kerbala

DOI:

https://doi.org/10.51699/cajmns.v7i2.3113

Keywords:

Type 2 Diabetes Mellitus, Glycemic Control, Metformin, Empagliflozin, Fasting Blood Glucose

Abstract

Background: Glycemic control is still the most important aspect of T2DM treatment sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, and metformin therapy has been shown to be effective and well tolerated in patients with T2DM and is first of the several recommended treatment options. Since empagliflozin is poorly studied solely or in comparison with metformin, the current study aims at comparing the influence of these drugs on glycemic level individually in patients with type 2 diabetes mellitus (T2DM). Method: The study was a quantitative experimental investigation (cross-sectional study) which contrasted the influence of metformin and empagliflozin on the short-term glycemic level, the metformin group included 30 newly diagnosed type 2 diabetic patients are treated with 1500mg of metformin divided 3 times daily and empagliflozin group includes 30 newly diagnosed type 2 diabetic patients are treated with 10mg of Empagliflozin once time daily). A total of fifty male patients aged (30-70) years were enrolled in this study. This study was performed from may 2022 to August 2022. All patients were already a newly diagnosed as diabetic patients with type 2 according to their medical history of diabetes and the ADA and WHO diagnostic criteria. Blood samples were analyzed for basic and advanced investigations. A complete blood cell count (CBC) was assessed via the URIT-3000Plus automated analyzer electrochemiluminescence (E.C.L.) technology for immunoassay analysis was used for measurement of Lipid profile, Liver function test, Renal function tests, Fasting blood glucose level, Hormones (insulin, TSH) and Hemoglobin A1C (HbA1c) Test. Also SPA antigen Sandwich immunoluminometric assay was used for Measurement of the immunological parameter glutamic acid decarboxylase antibody (GAD65). Results: the results of human samples were indicated that the metformin-treated group was shown a significant difference in the mean level of pre-post glucose test when compared to the empagliflozin-consuming group. The level of glucose was decreased significantly in the group treated with metformin more than in the group treated with empagliflozin, P values were <0.001. Interestingly, the repeated measurements of glucose level also indicated a significant difference, P values were <0.001. In conclusion: Metformin and empagliflozin have been shown through clinical studies an improved in the lowering blood glucose. Both medications were significantly improved glycemic control.

References

Wondafrash DZ, Nire’a AT, Tafere GG, Desta DM, Berhe DA, Zewdie KA. Thioredoxin-interacting protein as a novel potential therapeutic target in diabetes mellitus and its underlying complications. Diabetes Metab Syndr Obes. 2020 and 13:43.

Dec, Paldánius PM. Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. Diabetes Metab J. 2020 and 44(6):785-801.

American Diabetes Association Releases 2023 Standards of Care in Diabetes to Guide Prevention, Diagnosis, and Treatment for People Living with Diabetes. diabetes.org/newsroom/press-releases/2022/american-diabetes-association-2023-standards-care-diabetes-guide-for-prevention-diagnosis-treatment-people-living-with-diabetes. Published Dec. 12, 2022. Accessed Dec. 13, 2022.

Abusaib M, Ahmed M, Nwayyir HA, et al., Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults. Clin Med Insights Endocrinol Diabetes. 2020 Aug 19 and 13:1179551420942232.

Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. [Updated 2022 Aug 26]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. and 2000-.

Kotwas A, Karakiewicz B, Zabielska P, Wieder-Huszla S, Jurczak A. Epidemiological factors for type 2 diabetes mellitus: evidence from the Global Burden of Disease. Arch Public Health. 2021 Jun 22 and 79(1):110.

M, Moradinazar, et al.

Goyal R, Singhal M, Jialal I. Type 2 Diabetes. [Updated 2023 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing and https://www.ncbi.nlm.nih.gov/books/NBK513253/, 2023 Jan-. Available from:.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar and 10(1):107-111.

Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and (EASD). Diabetes Care Diabetes Care 2020 and 43:487–493.

Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023 Jun 26 and 17:1907-1932.

Drzewoski J, Hanefeld M. The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. Pharmaceuticals (Basel). 2021 Feb 5 and 14(2):122.

Dilworth, L., Facey, A. and Omoruyi, F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int. J. Mol. Sci. 2021, 22, 7644. https://doi.org/10.3390/ijms22147644.

Maccari, R. and Ottanà, R., 2022. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives. Journal of Medicinal Chemistry, 65(16), pp.10848-10881.

Cole, J. B., and Florez, J. C. (2020). Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol. 16 (7), 377–390. doi:10.1038/s41581-020-0278-5.

Sheleme, T., Mamo, G., Melaku, T., and Sahilu, T. (2020). Prevalence, patterns and predictors of chronic complications of diabetes mellitus at a large referral hospital in Ethiopia: A prospective observational study. Diabetes Metab. Syndr. Obes. 13, 4909–.

White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol 2016 and 1:692–9.

Wang B, Zhang M, Liu Y, et al. Utility of three novel insulin resistance- related lipid indices for predicting type 2 diabetes mellitus among people with normal fasting glucose in rural China. J Diabetes 2018 and 10:641–52.

Peng J, et al. BMJ Open 2021 and doi:10.1136/bmjopen-2020-042821, 11:e042821.

Wada M, Yano S, Hamano T, et al. Effect of serum cholesterol on insulin secretory capacity: Shimane CoHRE study. PLoS One 2016 and 11:e0149452.

Lin D, Qi Y, Huang C, et al. Associations of lipid parameters with insulin resistance and diabetes: a population-based study. Clin Nutr 2018 and 37:1423–9.

Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017 Oct 30 and 16(1):207.

Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther. 2012 Mar and 10(3):353-61.

Xepapadaki, E., Nikdima, I., Sagiadinou, E.C. et al. HDL and type 2 diabetes: the chicken or the egg?. Diabetologia 64, 1917–1926 (2021).

Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998 and 6:89–131.

Horakova, O., Kroupova, P., Bardova, K. et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci Rep 9, 6156 (2019).

McCreight LJ, Mari A, Coppin L, Jackson N, Umpleby AM, Pearson ER. Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. Diabetologia.2020 and 63(2):444-447.

Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546, https://doi.org/10.1038/nature13270 (2014).

Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Medicine 21, 506–511, https://doi.org/10.1038/nm.3787 (2015).